Liposomal prostaglandin E1 enhances optic nerve head blood flow in cats

Journal of Ocular Pharmacology and Therapeutics

Volumn 17, Issue 2, 2001, Pages 115-122

  Kitanishi, K ^a   Harino, S ^b   Suzuki, M ^b   Okamoto, N ^c   Reinach, P ^d,e  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b YODOGAWA CHRISTIAN HOSPITAL   (Japan)

^c OSAKA POLICE HOSPITAL   (Japan)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e Physiology and Cellular Biophysics ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOMAL PROSTAGLANDIN E1; PROSTAGLANDIN E1; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MONITORING; CAT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EYE BLOOD FLOW; INTRAOCULAR PRESSURE; LASER DOPPLER FLOWMETRY; MALE; NON INVASIVE MEASUREMENT; NONHUMAN; OPTIC NERVE; PERFUSION; VASODILATATION; ANIMAL; BLOOD FLOW; BLOOD FLOW VELOCITY; BLOOD PRESSURE; INTRAVENOUS DRUG ADMINISTRATION; OPTIC DISK; VASCULARIZATION;

ALPROSTADIL; ANIMALS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CATS; INFUSIONS, INTRAVENOUS; LASER-DOPPLER FLOWMETRY; MALE; OPTIC DISK; PLATELET AGGREGATION INHIBITORS; REGIONAL BLOOD FLOW; VASODILATOR AGENTS;

EID: 0034744589     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/10807680151125410     Document Type: Article

References (26)

1. Coupling of hormone receptors to adenylate cyclase of different cells by cell fusion
2. 1 on retinal vascular occlusive disease
3. Effects of anticoagulant therapy on retinal vein occlusion
4. 1 on human retinal vessels
5. 1 into the common carotid in ocular circulation
6. 1
7. 1 on choroidal circulation
8. Effects of prostaglandin on blood flow in the rabbit eye
9. 1 in man
10. Inactivation of prostaglandins by the lungs
11. Prostaglandins: Their disappearance from and release into the circulation
12. Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion
13. 1
14. 1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man
15. 1)
16. 1 incorporated in lipid microspheres on thrombus formation and thrombus disaggregation and its potential to target to the site of vascular lesions
17. Studies on 15-hydroxyprostaglandin dehydrogenase with various prostaglandin analogues
18. 1 on the microcirculation in chronic arterial occlusive disease
19. 1 in the treatment of ischemic ulcer of the extremities. A multi-clinical double-blind comparison with inositol niacinate
20. 1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders
21. 1 in patients with delayed cerebral vasospasm
22. 1 on random pattern flaps in rabbits
23. 1 on axial pattern flaps in rabbits
24. 1 incorporated in lipid microspheres for retinal vein occlusion
25. Treatment of impending branch retinal vein occlusion
26. 1 incorporated in lipid microspheres for occluded retinal vessels